Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 24121041)

1.

Circulating IL-35 in pancreatic ductal adenocarcinoma patients.

Jin P, Ren H, Sun W, Xin W, Zhang H, Hao J.

Hum Immunol. 2014 Jan;75(1):29-33. doi: 10.1016/j.humimm.2013.09.018. Epub 2013 Oct 11.

PMID:
24121041
2.

Decreased IL-35 levels in patients with immune thrombocytopenia.

Yang Y, Xuan M, Zhang X, Zhang D, Fu R, Zhou F, Ma L, Li H, Xue F, Zhang L, Yang R.

Hum Immunol. 2014 Aug;75(8):909-13. doi: 10.1016/j.humimm.2014.06.019. Epub 2014 Jun 30.

PMID:
24994465
3.

Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.

Jin A, Xu Y, Liu S, Jin T, Li Z, Jin H, Lin L, Lin Z.

Exp Mol Pathol. 2014 Feb;96(1):54-60. doi: 10.1016/j.yexmp.2013.11.003. Epub 2013 Nov 18.

PMID:
24263054
4.

Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma.

Weng S, Wang H, Chen W, Katz MH, Chatterjee D, Lee JE, Pisters PW, Gomez HF, Abbruzzese JL, Fleming JB, Wang H.

Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1336-43. doi: 10.1158/1055-9965.EPI-12-0223. Epub 2012 Jun 4.

5.

Increased B cell-activating factor promotes tumor invasion and metastasis in human pancreatic cancer.

Koizumi M, Hiasa Y, Kumagi T, Yamanishi H, Azemoto N, Kobata T, Matsuura B, Abe M, Onji M.

PLoS One. 2013 Aug 6;8(8):e71367. doi: 10.1371/journal.pone.0071367. Print 2013.

6.

High expression of interleukin-22 and its receptor predicts poor prognosis in pancreatic ductal adenocarcinoma.

Wen Z, Liao Q, Zhao J, Hu Y, You L, Lu Z, Jia C, Wei Y, Zhao Y.

Ann Surg Oncol. 2014 Jan;21(1):125-32. doi: 10.1245/s10434-013-3322-x. Epub 2013 Oct 17.

PMID:
24132627
7.

An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma.

Dima SO, Tanase C, Albulescu R, Herlea V, Chivu-Economescu M, Purnichescu-Purtan R, Dumitrascu T, Duda DG, Popescu I.

Pancreas. 2012 Oct;41(7):1001-7. doi: 10.1097/MPA.0b013e3182546e13.

PMID:
22722257
8.

MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis.

Kadera BE, Li L, Toste PA, Wu N, Adams C, Dawson DW, Donahue TR.

PLoS One. 2013 Aug 22;8(8):e71978. doi: 10.1371/journal.pone.0071978. eCollection 2013.

9.

Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.

Chang DZ, Ma Y, Ji B, Liu Y, Hwu P, Abbruzzese JL, Logsdon C, Wang H.

J Hematol Oncol. 2012 Apr 4;5:15. doi: 10.1186/1756-8722-5-15.

10.

Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls.

Carlsen AL, Joergensen MT, Knudsen S, de Muckadell OB, Heegaard NH.

Pancreas. 2013 Oct;42(7):1107-13. doi: 10.1097/MPA.0b013e318296bb34.

PMID:
24048453
11.

Molecular markers associated with lymph node metastasis in pancreatic ductal adenocarcinoma by genome-wide expression profiling.

Hirono S, Yamaue H, Hoshikawa Y, Ina S, Tani M, Kawai M, Ushijima M, Matsuura M, Saiki Y, Saiura A, Yamamoto J, Miki Y, Noda T.

Cancer Sci. 2010 Jan;101(1):259-66. doi: 10.1111/j.1349-7006.2009.01359.x. Epub 2009 Sep 10.

PMID:
19817750
12.

Expression of HOXC8 is inversely related to the progression and metastasis of pancreatic ductal adenocarcinoma.

Adwan H, Zhivkova-Galunska M, Georges R, Eyol E, Kleeff J, Giese NA, Friess H, Bergmann F, Berger MR.

Br J Cancer. 2011 Jul 12;105(2):288-95. doi: 10.1038/bjc.2011.217. Epub 2011 Jun 28.

13.

SERPINB5 and AKAP12 - expression and promoter methylation of metastasis suppressor genes in pancreatic ductal adenocarcinoma.

Mardin WA, Petrov KO, Enns A, Senninger N, Haier J, Mees ST.

BMC Cancer. 2010 Oct 12;10:549. doi: 10.1186/1471-2407-10-549.

14.

Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.

Poruk KE, Firpo MA, Scaife CL, Adler DG, Emerson LL, Boucher KM, Mulvihill SJ.

Pancreas. 2013 Mar;42(2):193-7. doi: 10.1097/MPA.0b013e31825e354d.

15.

Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.

Shaw VE, Lane B, Jenkinson C, Cox T, Greenhalf W, Halloran CM, Tang J, Sutton R, Neoptolemos JP, Costello E.

Mol Cancer. 2014 May 20;13:114. doi: 10.1186/1476-4598-13-114.

16.

Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients.

Guo S, Jing W, Hu X, Zhou X, Liu L, Zhu M, Yin F, Chen R, Zhao J, Guo Y.

Int J Cancer. 2014 Mar 15;134(6):1369-78. doi: 10.1002/ijc.28471. Epub 2013 Oct 3.

PMID:
24037692
17.

Expression and clinical significance of apolipoprotein E in pancreatic ductal adenocarcinoma.

Chen J, Chen LJ, Yang RB, Xia YL, Zhou HC, Wu W, Lu Y, Hu LW, Zhao Y.

Med Oncol. 2013;30(2):583. doi: 10.1007/s12032-013-0583-y. Epub 2013 Apr 23.

PMID:
23609192
19.

Association of increased DNA methyltransferase expression with carcinogenesis and poor prognosis in pancreatic ductal adenocarcinoma.

Zhang JJ, Zhu Y, Zhu Y, Wu JL, Liang WB, Zhu R, Xu ZK, Du Q, Miao Y.

Clin Transl Oncol. 2012 Feb;14(2):116-24. doi: 10.1007/s12094-012-0770-x.

PMID:
22301400
20.

Yes-associated protein (YAP65) in relation to Smad7 expression in human pancreatic ductal adenocarcinoma.

Guo J, Kleeff J, Zhao Y, Li J, Giese T, Esposito I, B├╝chler MW, Korc M, Friess H.

Int J Mol Med. 2006 May;17(5):761-7.

PMID:
16596258
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk